Coexpression of CMP‐sialic acid transporter reduces N ‐glycolylneuraminic acid levels of recombinant glycoproteins in Chinese hamster ovary cells

2019 ◽  
Vol 116 (11) ◽  
pp. 2815-2822 ◽  
Author(s):  
Dong Gyun Kang ◽  
Chang Sup Kim ◽  
Hyung Joon Cha
10.1038/15104 ◽  
1999 ◽  
Vol 17 (11) ◽  
pp. 1116-1121 ◽  
Author(s):  
S. Weikert ◽  
D. Papac ◽  
J. Briggs ◽  
D. Cowfer ◽  
S. Tom ◽  
...  

The Analyst ◽  
2016 ◽  
Vol 141 (20) ◽  
pp. 5799-5809 ◽  
Author(s):  
Claire L. Schofield ◽  
María J. Marín ◽  
Martin Rejzek ◽  
Paul R. Crocker ◽  
Robert A. Field ◽  
...  

Glyconanoparticles have been synthesised for the specific detection of mSiglec-E in solution and expressed on the surface of CHO cells.


Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document